Cancer Drug Shop BioVex Markets Legacy Technology for shRNA Delivery

The technology comprises replication-defective herpes simplex viruses that express shRNAs and can be delivered to the nervous system both in vitro and in vivo, and the company has been marketing it for research applications.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.